Bolt Biotherapeutics Inc [BOLT] stock prices are up 4.44% to $0.68 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BOLT shares have gain 8.45% over the last week, with a monthly amount glided 16.42%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Bolt Biotherapeutics Inc [NASDAQ: BOLT] stock has seen the most recent analyst activity on January 06, 2022, when Morgan Stanley downgraded its rating to a Equal-Weight. Previously, SVB Leerink started tracking the stock with Outperform rating on March 02, 2021, and set its price target to $36. On March 02, 2021, Stifel initiated with a Buy rating and assigned a price target of $40 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $45 on March 02, 2021. Guggenheim initiated its recommendation with a Buy and recommended $42 as its price target on March 02, 2021.
The stock price of Bolt Biotherapeutics Inc [BOLT] has been fluctuating between $0.55 and $1.56 over the past year. Currently, Wall Street analysts expect the stock to reach $1 within the next 12 months. Bolt Biotherapeutics Inc [NASDAQ: BOLT] shares were valued at $0.68 at the most recent close of the market. An investor can expect a potential return of 47.06% based on the average BOLT price forecast.
Analyzing the BOLT fundamentals
The Bolt Biotherapeutics Inc [NASDAQ:BOLT] reported sales of 11.17M for trailing twelve months, representing a drop of -11.03%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -6.63%, Pretax Profit Margin comes in at -5.93%, and Net Profit Margin reading is -5.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.53, Equity is -0.61 and Total Capital is -0.7. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6469 points at the first support level, and at 0.6144 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7149, and for the 2nd resistance point, it is at 0.7504.
Ratios To Look Out For
It’s worth pointing out that Bolt Biotherapeutics Inc [NASDAQ:BOLT]’s Current Ratio is 4.28. In addition, the Quick Ratio stands at 4.28 and the Cash Ratio stands at 0.35. Considering the valuation of this stock, the price to sales ratio is 2.33, the price to book ratio is 0.30.
Transactions by insiders
Recent insider trading involved Quinn William P., Chief Financial Officer, that happened on Dec 12 ’23 when 7500.0 shares were purchased. Chief Financial Officer, Quinn William P. completed a deal on Dec 06 ’23 to buy 2500.0 shares. Meanwhile, Director ENGLEMAN EDGAR sold 0.12 million shares on Nov 30 ’23.
